eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 150 blog entries.
9 05, 2019

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

2019-05-09T20:50:39+00:00

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update First-Ever Phase 3 HDV International “D-LIVR” Study UnderwayNDA and MAA filings for Progeria & Progeroid Laminopathies planned in 2019Strong Balance Sheet with Recent Financing CompletedPALO ALTO, Calif., May 9, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted [...]

Eiger BioPharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update2019-05-09T20:50:39+00:00
30 04, 2019

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 2019

2019-04-30T13:24:14+00:00

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 2019 PALO ALTO, Calif., April 30, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will participate and present a corporate update at the ChinaBio® Partnering [...]

Eiger Bio to Present at Upcoming ChinaBio® Partnering Forum 20192019-04-30T13:24:14+00:00
17 04, 2019

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock – 4/17/2019

2019-04-18T13:23:00+00:00

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock - 4/17/2019 Palo Alto, Calif., April 17, 2019, Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share. All of the shares are being [...]

Eiger BioPharmaceuticals Announces Pricing of Public Offering of Common Stock – 4/17/20192019-04-18T13:23:00+00:00
17 04, 2019

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock 4/17/2019

2019-04-18T13:18:13+00:00

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock 4/17/2019 Palo Alto, Calif., April 17, 2019, Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering are to be sold by Eiger. In [...]

Eiger BioPharmaceuticals Announces Proposed Public Offering of Common Stock 4/17/20192019-04-18T13:18:13+00:00
15 04, 2019

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors

2019-04-15T12:26:41+00:00

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors PALO ALTO, Calif., April 15, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for serious rare and ultra-rare diseases, announced today the appointment of Amit K. Sachdev, JD to its Board [...]

Eiger BioPharmaceuticals Appoints Market Access, Public Policy Expert, and Biotech Veteran Amit K. Sachdev to Board of Directors2019-04-15T12:26:41+00:00
11 04, 2019

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019

2019-04-11T21:56:39+00:00

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 2019 Improved Tolerability in HDV-infected Patients vs Historical Peginterferon Alfa Post-treatment Endpoint Results to be Discussed with Regulatory Agencies PALO ALTO, Calif., April 11, 2019 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused [...]

Eiger Announces 36% Durable Virologic Response at 24 Weeks Post-Treatment with Peginterferon Lambda in Phase 2 LIMT HDV Study at The International Liver Congress™ 20192019-04-11T21:56:39+00:00
26 03, 2019

Eiger BioPharmaceuticals to Participate in Conferences in April

2019-03-26T13:24:24+00:00

Eiger BioPharmaceuticals to Participate in Conferences in April PALO ALTO, Calif. – March 26, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will present at upcoming investor, scientific, and orphan drug conferences in April. C. Wainwright Global [...]

Eiger BioPharmaceuticals to Participate in Conferences in April2019-03-26T13:24:24+00:00
25 03, 2019

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019

2019-03-25T17:57:47+00:00

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019 Statistically Significant Reduction in Hyperinsulinemic Hypoglycemia Reduced Rates of Hypoglycemia and Rescue in Outpatient Setting PALO ALTO, Calif., March 25, 2019 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization [...]

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 20192019-03-25T17:57:47+00:00
20 03, 2019

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019

2019-03-20T13:29:54+00:00

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 2019 PALO ALTO, Calif., March 20, 2019 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that David Cory, President and CEO, will present a corporate update at the [...]

Eiger BioPharmaceuticals Management Team to Present and Participate in China Healthcare Investment Conference 20192019-03-20T13:29:54+00:00
14 03, 2019

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

2019-03-14T22:50:48+00:00

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update Began 2019 with $100.4 million in cash, cash equivalents & short-term investmentsEnrollment of Phase 3 D-LIVR Study in HDV planned by end of 2019NDA and MAA filings for Progeria and Progeroid Laminopathies planned in 2019 PALO ALTO, Calif., March 14, 2019 [...]

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update2019-03-14T22:50:48+00:00

About Us

EigerBio Logo

We are a values-driven company that works to embody Integrity, Passion, Accountability, Creativity, and Teamwork in the pursuit of our mission.

Privacy Policy | Terms & Conditions

Therapeutic Areas

Hepatitis Delta
Post-bariatric Hypoglycemia
Hutchinson-Gilford Progeria Syndrome
Home
About Eiger
Pipeline
News
Investors
Careers
Contact Us

Contact

Eiger BioPharmaceuticals, Inc.
2155 Park Boulevard
Palo Alto, CA 94306

Phone: 1-877-899-2051
Fax: 650-618-1621
Email: info@eigerbio.com

Click Here for Directions

Eiger BioPharmaceuticals © 2018 | All Rights Reserved
Toggle Sliding Bar Area